Since RA190 treatment in vitro reduced the levels of key suppressive molecules produced by MDSC and their capacity to suppress CD8+ T cell proliferation, we sought to determine its impact on ovarian tumor control, anti-tumor immunity and the survival of a tumor bearing host. Here, CD8A is linked to ovarian neoplasm.